zorevunersen Evidence: Trial Results and Peer-Reviewed Publications

Hipa.ai Research · Source: PubMed & ClinicalTrials.gov / AACT · Last updated:

The clinical evidence base for zorevunersen comprises 1 peer-reviewed publications across 1 journals, 0 pivotal-trial primary-outcome rows reported to ClinicalTrials.gov, spanning indications including Epilepsies, Myoclonic. Most recent publication: Zorevunersen in Children and Adolescents with Dravet Syndrome., N Engl J Med, 2026.

Top peer-reviewed publications

Curated set of pivotal-trial result papers and recent publications in high-tier journals.

  1. Zorevunersen in Children and Adolescents with Dravet Syndrome.
    Laux L, Sullivan J, Perry MS, et al. · N Engl J Med · 2026
    PubMed: PMID 41780062 · NCT04740476 · Epilepsies, Myoclonic

Publications by year

20262026: 1 publications.

2026
1

Publications by indication

Epilepsies, Myoclonic (1)

Publications by journal

All zorevunersen publications (1)

2026 (1 paper)

  1. Zorevunersen in Children and Adolescents with Dravet Syndrome.
    Laux L, Sullivan J, Perry MS, et al. · N Engl J Med · 2026 · Derived
    PubMed: PMID 41780062 · NCT04740476 · Epilepsies, Myoclonic

Sources and methodology

This page summarizes published evidence for general reference and does not constitute medical advice. For clinical decisions, consult the linked primary publications and your healthcare provider. Data sourced from PubMed and the ClinicalTrials.gov / AACT database maintained by the Clinical Trials Transformation Initiative (CTTI).